AMSTERDAM, March 30, 2016 /PRNewswire/ -- Royal
Philips (NYSE: PHG; AEX: PHIA) today introduced the first
commercially available MR-only simulation solution indicated for
prostate cancer radiation oncology treatment planning in
the United States. Philips has
achieved 510(k) clearance from the Food and Drug Administration
(FDA) for its MRCAT (Magnetic Resonance for Calculating
ATtenuation) solution as part of its Ingenia MR-RT platform. This
imaging approach supports radiation departments that want to rely
on MRI as their primary imaging modality for prostate cancer
treatment planning.
Prostate cancer is the most common cancer among American
men, causing approximately 27,540 deaths
annually1. Approximately one million U.S.
patients2 undergo radiotherapy annually, and imaging
plays a vital role. Current clinical practice often uses a combined
approach using both MR and CT images, but this can lead to image
misalignment and registration uncertainties that could impact
targeting and treatment. It also puts pressure on patient burden,
workflows and costs. MR-only simulation not only alleviates
additional scans for the patient, but improves physician workflow
and could potentially reduce provider costs, as compared to MR-CT
workflow.
"Successful cancer treatment depends on the quality and accuracy
of the radiation therapy plan, making imaging a critical piece in
determining course of treatment," said Dr. Rodney Ellis, vice chairman of Radiation
Oncology at the University Hospitals Seidman Cancer Center. "The
real power of MR-only simulation is that it enables us to develop
personalized treatment plans. It can also streamline our
workflows, which in turn reduces the burden on prostate cancer
patients and the health system. Moreover, it can eliminate the
systematic errors introduced by MR-CT registration."
As part of its Ingenia MR-RT platform for MR simulation,
Philips' new MRCAT solution allows physicians treating prostate
cancer patients to adopt a single-modality imaging approach that
provides high quality soft-tissue contrast for target delineation,
as well as density information for dose calculations. To produce
the density information standard for CT, Philips has integrated
fast and robust imaging protocols to obtain CT-like images on the
MR console. Philips' MR-only simulation solution has also received
CE mark and is available globally.
"MR-only simulation is a continuation of Philips' commitment to
driving image-guided therapy in the market. Where CT solutions have
played a leading role in past radiotherapy treatments, MR takes an
innovative approach by providing physicians with increased
soft-tissue visualization and functional imaging capabilities to
help improve treatment plans," said Lizette
Warner, Ph.D., manager of clinical science MR therapy,
North America, Philips. "MR-only
simulation makes MR more accessible for hospitals and physicians,
transforming the way care is delivered and supporting our customers
in improving care for oncology patients who require
radiotherapy."
Philips' radiation oncology solutions work along the health
continuum to improve patient care, provide excellent value and
expand access to care. Through collaboration with clinicians,
Philips is able to fully integrate the imaging, simulation,
planning and therapy tools required for delivering efficient and
personalized radiation oncology care to patients.
Philips Radiation Oncology Systems (PROS) allows clinicians to
move from scan to plan right at the CT console, with the enhanced
Tumor LOC v4.2 virtual simulation and patient marking application
enabled by the integration of Pinnacle3 and Brilliance
CT Big Bore:
- Brilliance CT Big Bore – Focusing on what matters most in
radiation oncology, Philips Brilliance CT Big Bore delivers high
quality imaging while enabling personalized dose based on the
clinical needs of patients. Designed to meet the specific needs of
radiation oncology and CT simulation, Philips' CT solutions focus
on accuracy, patient positioning, imaging performance and a
radiation therapy process that integrates seamlessly with clinical
workflows, keeping the patient at the center of everything.
- Pinnacle3 Auto Planning – Recognized as a treatment
planning system for external beam radiotherapy, this system
provides accuracy and reliability independent of the treatment
delivery system. With enhanced efficiency and standardization,
Pinnacle3 Auto-Planning makes the IMRT planning process
faster, less labor intensive and more reproducible.
For further information, please contact:
Adrienne Smith
Philips Diagnostic Imaging
Tel: +1 781-277-1170
Email: Adrienne.Smith@philips.com
Steve Klink
Philips Group Communications
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA)
is a leading health technology company focused on improving
people's health and enabling better outcomes across the health
continuum from healthy living and prevention, to diagnosis,
treatment and home care. Philips leverages advanced technology and
deep clinical and consumer insights to deliver integrated
solutions. The company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips' wholly owned
subsidiary Philips Lighting is the global leader in lighting
products, systems and services. Headquartered in the Netherlands, Philips posted 2015 sales of
EUR 24.2 billion and employs
approximately 104,000 employees with sales and services in more
than 100 countries. News about Philips can be found at
www.philips.com/newscenter.
1 American Cancer Society, Key Statistics
for Prostate Cancer, 2016
2 IMV, 2014
Radiation Therapy Market Summary Report
Logo -
http://photos.prnewswire.com/prnh/20140122/NE50581LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/philips-introduces-first-commercial-mr-only-solution-for-prostate-cancer-treatment-planning-in-the-us-300242936.html
SOURCE Royal Philips